Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY) today announced that it will report third quarter 2023 financial results on Tuesday, October 31, 2023, before the open of the U.S. financial markets.
| |
| [17-October-2023] |
| PLYMOUTH MEETING, Pa., Oct. 17, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2023 financial results on Tuesday, October 31, 2023, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on October 31, 2023, at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial (800) 245-3047 (domestic) or +1 (203) 518-9765 (international), and reference passcode HRMYQ323. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences Investor Contact: Harmony Biosciences Media Contact:
SOURCE Harmony Biosciences | ||
Company Codes: NASDAQ-NMS:HRMY |
View original content to download multimedia:
